Cosentyx 75 mg/0.5 mL, 150 mg/mL, 300 mg/2mL SOLUTION FOR INJECTION
PDF Leaflet Revision Date: 17 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Moderate to severe plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, juvenile idiopathic arthritis, and hidradenitis suppurativa.
Dosage (summary)
Adults: 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then monthly. Pediatric: Dose based on weight.
Onset of Action / Duration
Onset: 16 weeks, Duration: Varies.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid during breastfeeding.
Key Drug Interactions
- Live vaccines
- Immunosuppressants
Contraindications
- Hypersensitivity
- Active infections
- Pregnancy
- Breastfeeding
Common side effects
- Upper respiratory tract infections
- Headache
- Fatigue
- Diarrhea
Counselling Points
- Monitor for signs of infection
- Avoid live vaccines
- Educate on injection technique
Serious warnings
- Risk of infections
- Hypersensitivity reactions
- Eczematous eruptions
Important Disclaimer
The Cosentyx 75 mg/0.5 mL, 150 mg/mL, 300 mg/2mL SOLUTION FOR INJECTION professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
